Cadila Pharmaceuticals

We extend our commitment to critical care through a focused, patient-centric approach to intensive therapy. Cadila Pharma’s dedicated critical care division delivers high-quality, evidence-based therapies to critically ill patients, ensuring effective and reliable treatment.

Our therapeutic focus

We offer a comprehensive portfolio of high-quality, evidence-based medicines across multiple therapeutic segments. All products in the portfolio are developed at our world-class, regulatory-compliant manufacturing facilities in Dholka and at our Udaipur Plant, which is one of the largest in Asia and adheres to the highest global standards, further building our lyophilised product manufacturing capabilities at par with international quality standards.

Sepsivac
Indigenously developed immunomodulator
Calcirol Blu
Patented innovation
Antifungals
Supporting complete care with fungal treatments
Antibiotics
Precision and quality care
Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication
downWhiteCurveArrow

Corporate Identification No : U24231GJ1991PLC015132

©2026 Cadila Pharmaceuticals. All rights reserved